多种肿瘤标志物蛋白芯片在肺癌中的检测及其应用价值

Multiple Tumor Markers Protein Biochip in Detection of Lung Cancer and its Application Value

[目的]探讨多种肿瘤标志物蛋白芯片检测系统(C鄄12)在鉴别肺癌的临床分期、病理类型和预后评估中的价值。[方法]应用该芯片检测系统测定143例肺癌病人血清中12种肿瘤标志物(CA19鄄9,NSE,CEA,CA242,Fe,HCG,AFP,Free鄄PSA,PSA,CA125,HGH,CA15鄄3)的水平。[结果]不同病理类型的肺癌之间各项肿瘤标志物的阳性率、血清水平和C鄄12总阳性率均无显著性差异;不同分期的肺癌之间C鄄12总阳性率无显著性差异,但CA19鄄9阳性率及血清水平存在显著性差异(P<0.05),而其他各项肿瘤标志物的阳性率及血清水平均无显著性差异。[结论]肺癌组织能够产生CA19鄄9,CA19鄄9与肺癌的临床分期有一定的相关性。该检测系统在鉴别肺癌的临床分期、病理类型和预后评估方面价值有限,尚需作某些肿瘤标志物的增减以便更有效地指导临床。

To evaluate the value of detective system(C-12) of multiple tumor markers protein biochip for clinical staging, pathologic classification and prognostic evaluation in lung cancer. ProteinChip Array technology was used to detect the serum levels of 12 tumor markers, including CA19-9, NSE, CEA, CA242, Fe, HCG, AFP, Free-PSA, CA125, HGH and CA15-3 in 143 cases with lung cancer. There was no significantly difference in total positive rate and serum levels of C-12 among different pathologic types and stages of lung cancer. There was significantly difference in the positive rate and serum level of CA19-9 among various clinical stages(P<0.05), and the total positive rate of C-12 and the positive rate and serum levels of other tumor markers were similar in different stages of lung cancer. [Conclusion] CA19-9 can be created by human lung cancer tissues, and its serum level correlates with clinical stages of lung cancer. The detective system of multiple tumor markers protein biochip has limited application for clinical staging, pathologic classification and prognostic evaluation in patients with lung cancer.